NASDAQ:PYPD PolyPid (PYPD) Stock Price, News & Analysis → My next big prediction isn’t a prediction (From Porter & Company) (Ad) Free PYPD Stock Alerts $5.28 -0.21 (-3.83%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$5.28▼$5.2850-Day Range$5.03▼$6.9952-Week Range$3.57▼$17.25Volume398 shsAverage Volume8,092 shsMarket Capitalization$8.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get PolyPid alerts: Email Address PolyPid MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.33% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.97Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.72) to ($2.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.77 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for PolyPid. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.33% of the float of PolyPid has been sold short.Short Interest Ratio / Days to CoverPolyPid has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PolyPid has recently decreased by 36.99%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPolyPid does not currently pay a dividend.Dividend GrowthPolyPid does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PYPD. Previous Next 3.3 News and Social Media Coverage News SentimentPolyPid has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for PolyPid this week, compared to 1 article on an average week.MarketBeat Follows2 people have added PolyPid to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PolyPid insiders have not sold or bought any company stock.Percentage Held by Insiders24.70% of the stock of PolyPid is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.28% of the stock of PolyPid is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PolyPid are expected to grow in the coming year, from ($3.72) to ($2.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PolyPid is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PolyPid is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.Get the stock ticker here >>> About PolyPid Stock (NASDAQ:PYPD)PolyPid Ltd., a clinical-stage pharmaceutical company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which helps in the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.Read More PYPD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PYPD Stock News HeadlinesMarch 13, 2024 | americanbankingnews.comShort Interest in PolyPid Ltd. (NASDAQ:PYPD) Decreases By 37.0%March 12, 2024 | americanbankingnews.comPolyPid (NASDAQ:PYPD) Trading Up 0.6%March 18, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…February 28, 2024 | globenewswire.comPolyPid to Participate in Barclays 26th Annual Global Healthcare ConferenceFebruary 19, 2024 | finance.yahoo.comPolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?February 15, 2024 | finance.yahoo.comPolyPid Ltd. (NASDAQ:PYPD) Q4 2023 Earnings Call TranscriptFebruary 14, 2024 | markets.businessinsider.comBuy Rating for PolyPid Amid Positive D-PLEX100 Trial Prospects and Strategic Market PositioningFebruary 14, 2024 | finanznachrichten.dePolyPid Ltd.: PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 18, 2024 | Crypto 101 Media (Ad)Like Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. February 14, 2024 | finance.yahoo.comPolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 14, 2024 | globenewswire.comPolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 12, 2024 | finanznachrichten.dePolyPid Ltd.: PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 TrialFebruary 12, 2024 | finance.yahoo.comPolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 TrialJanuary 31, 2024 | finance.yahoo.comPolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024January 5, 2024 | msn.comWhy Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day SessionJanuary 5, 2024 | msn.comCyclacel Pharmaceuticals, Angiodynamic among healthcare moversJanuary 4, 2024 | uk.finance.yahoo.comPolyPid Ltd. (PYPD)January 4, 2024 | msn.comPolyPid looks to raise $16.2M through private placementJanuary 4, 2024 | finance.yahoo.comPolyPid Announces Private Placement for $16 Million in Gross ProceedsNovember 12, 2023 | finance.yahoo.comPolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Call TranscriptNovember 12, 2023 | investing.comEarnings call: PolyPid's Q3 2023 financial results show decreased expenses and progress in SHIELD II trialNovember 8, 2023 | finance.yahoo.comPolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsNovember 7, 2023 | benzinga.comPolyPid's Earnings: A PreviewNovember 7, 2023 | finance.yahoo.comPolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of DirectorsNovember 1, 2023 | finance.yahoo.comPolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023October 24, 2023 | msn.comBarclays Maintains Polypid (PYPD) Equal-Weight RecommendationOctober 19, 2023 | finance.yahoo.comPolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price RuleSee More Headlines Receive PYPD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PolyPid and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today3/18/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:PYPD CUSIPN/A CIK1611842 Webwww.polypid.com Phone972-74-719-5700FaxN/AEmployees57Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($19.6823) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-450.37% Return on Assets-101.27% Debt Debt-to-Equity Ratio2.17 Current Ratio0.83 Quick Ratio0.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.27) per share Price / Book-4.16Miscellaneous Outstanding Shares1,650,000Free Float1,245,000Market Cap$8.71 million OptionableOptionable Beta1.43 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMs. Dikla Czaczkes Akselbrad (Age 51)CEO & Director Comp: $422.33kMs. Dalit Hazan (Age 53)Executive Vice President of R&D and Clinical & Regulatory Affairs Comp: $312.25kMr. Ori Warshavsky (Age 46)Chief Operating Officer - US Comp: $335.52kMr. Jonny Missulawin (Age 37)Chief Financial Officer Ms. Maria RubinVice President of OperationsMr. Tal VilnaiGeneral Counsel & Corporate SecretaryMs. Rivi Lev-ariVice President of Human ResourceDr. Jean-Marc Hagai Pharm.D.Chief Commercial OfficerMore ExecutivesKey CompetitorsProSomnusNASDAQ:OSAVapothermNYSE:VAPOIntelligent Bio SolutionsNASDAQ:INBSTitan MedicalNASDAQ:TMDIFNeuroMetrixNASDAQ:NUROView All Competitors PYPD Stock Analysis - Frequently Asked Questions Should I buy or sell PolyPid stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PolyPid in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PYPD shares. View PYPD analyst ratings or view top-rated stocks. How have PYPD shares performed in 2024? PolyPid's stock was trading at $3.80 at the beginning of the year. Since then, PYPD stock has increased by 38.9% and is now trading at $5.28. View the best growth stocks for 2024 here. Are investors shorting PolyPid? PolyPid saw a decrease in short interest in February. As of February 29th, there was short interest totaling 4,600 shares, a decrease of 37.0% from the February 14th total of 7,300 shares. Based on an average daily volume of 7,400 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.3% of the shares of the company are short sold. View PolyPid's Short Interest. When is PolyPid's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our PYPD earnings forecast. How were PolyPid's earnings last quarter? PolyPid Ltd. (NASDAQ:PYPD) announced its quarterly earnings results on Wednesday, February, 14th. The company reported ($3.97) EPS for the quarter, missing analysts' consensus estimates of ($2.17) by $1.80. When did PolyPid's stock split? PolyPid shares reverse split before market open on Thursday, September 21st 2023. The 1-30 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of PolyPid own? Based on aggregate information from My MarketBeat watchlists, some companies that other PolyPid investors own include Advanced Micro Devices (AMD), Moderna (MRNA), Sorrento Therapeutics (SRNE), Trevena (TRVN), Cardinal Health (CAH), Genocea Biosciences (GNCA), LightPath Technologies (LPTH), Stride (LRN) and Livongo Health (LVGO). When did PolyPid IPO? (PYPD) raised $50 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 3,100,000 shares at $15.00-$17.00 per share. Barclays and BMO Capital Markets acted as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers. Who are PolyPid's major shareholders? PolyPid's stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of PolyPid? Shares of PYPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PYPD) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Gates Bets on $15 Trillion BonanzaWeiss RatingsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.